Example: Heart Attack

Search clinical trials for: Bismuth tripotassium dicitrate

Total 96 results

NCT02788123

Terminated

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy

Conditions: NSAID-induced Gastropathy
NCT00669955

Completed

Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

Conditions: Helicobacter Infections
NCT01335334

Unknown status

H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study

Conditions: H. Pylori Infection
NCT01876108

Completed

The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease

Conditions: Fatty Liver; Liver Dysfunction; Insulin Resistance
NCT03925818

Terminated

Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication

Conditions: Helicobacter Pylori Infection
NCT03108287

Completed

Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori

Conditions: Helicobacter Pylori Infection
NCT04527055

Enrolling by invitation

The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

Conditions: Helicobacter Pylori Infection; Dysbiosis; Probiotics
NCT04101708

Not yet recruiting

A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients

Conditions: Helicobacter Pylori
NCT00520949

Completed

Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection

Conditions: Treatment of Helicobacter Pylori
NCT04566211

Recruiting

Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy.

Conditions: Helicobacter Pylori Infection
NCT03968302

Completed

ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

Conditions: Helicobacter Pylori Infection
NCT03321773

Recruiting

Comparing the Efficacy of 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth Therapy

Conditions: Helicobacter Pylori Infection
NCT02541864

Completed

Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication

Conditions: Helicobacter Pylori Infection
NCT02547038

Completed

Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy

Conditions: Helicobacter Pylori Infection
NCT02004197

Completed

Quadruple and Phytomedicine-based Therapies in H. Pylori Infection

Conditions: Helicobacter Pylori [H. Pylori] as the Cause of Diseases
NCT02894268

Unknown status

Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy

Conditions: Helicobacter Pylori Infection
NCT02547025

Recruiting

Personalized Treatment for Refractory H Pylori Infection

Conditions: Helicobacter Pylori Infection
NCT01306786

Completed

Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication

Conditions: Helicobacter Pylori Infection
NCT04359966

Not yet recruiting

Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia

Conditions: Helicobacter Pylori Infection; Eradication Treatments
NCT02555852

Completed

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Conditions: Gastroesophageal Reflux Disease (GERD); Community-acquired Pneumonia
NCT01805934

Completed

Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection

Conditions: Rescue Therapy for Helicobacter Pylori
NCT04107194

Recruiting

Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

Conditions: Helicobacter Pylori Infection; Antibiotic Resistant Infection; Antibiotic Resistant Strain
NCT04397445

Completed

Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration

Conditions: Ranitidine Adverse Reaction; Pharmacokinetics; Food-drug Interaction
NCT03145012

Active, not recruiting

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Conditions: Cancer
NCT02195804

Completed

Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers

Conditions: Healthy